Investment case
Outlook Therapeutics, Inc.
OTLK · 3 developments mapped · last assessed 2026-08-14
Market Ontology has mapped 3 macro, policy, and market developments to Outlook Therapeutics, Inc. since 2026-08-13. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for OTLK yet, so no modelled value is shown. The OTLK valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run OTLK on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Outlook Therapeutics, Inc. Follow-On — $51M
Dilution from new share issuance, potential downward pressure on share price due to increased supply, and uncertainty regarding the use of proceeds relative to the dilution.
· Moves shares outstanding, cost of equity (due to increased risk perception), future cash flow per share
- Open question
Outlook Therapeutics, Inc. Follow-On — $55M
Direct dilution from equity offering; improved liquidity and funding for operations/development; potential downward pressure on stock price due to increased supply and offering price.
· Moves future cash flow discount rate (wacc), per share metrics (eps, fcf/share), probability of successful drug development/commercialization
What changed, by assumption
- 2026-08-14Outlook Therapeutics, Inc. Follow-On — $51M
- 2026-08-13Outlook Therapeutics Follow-On — $55M
- 2026-08-13Outlook Therapeutics, Inc. Follow-On — $55M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-13 | Share count | Bullish | The issuance of common stock and warrants in a $55M public offering will increase the total shares outstanding. | 0.90 |
| 2026-08-13 | Share count | Bullish | Public offering of common stock and warrants will increase the total shares outstanding upon closing and exercise. | 0.90 |
| 2026-08-13 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-13 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-06-16 | Revenue | Bullish | FDA acceptance of BLA resubmission for ONS-5010 with a PDUFA date in July 2026 moves the company closer to commercialization and first-ever revenue from this product. | 0.90 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-14 | Outlook Therapeutics, Inc. Follow-On — $51M | Bearish | 1-3m | 0.80 |
| 2026-08-13 | Outlook Therapeutics, Inc. Follow-On — $55M | mixed | 1-3m | 0.70 |
| 2026-08-13 | Outlook Therapeutics Follow-On — $55M | Bearish | 1-3m | 0.80 |